Azitra, Inc. (NYSEAMERICAN:AZTR) Shares Shorted: Short Interest Up 172.3% in October

Azitra, Inc. (NYSEAMERICAN:AZTR – Get Free Report) was the recipient of a large increase in short interest during the month of October. As of October 30th, there was short interest totaling 305,802 shares, an increase of 172.3% from the October 15th total of 112,293 shares. Currently, 5.1% of the shares of the stock are sold short. Based on an average trading volume of 14,623,589 shares, the short-interest ratio is currently 0.0 days.

Azitra Stock Performance

NYSEAMERICAN:AZTR traded down $0.06 during mid-day trading on Friday, hitting $0.61. 80,169 shares of the company’s stock traded hands, compared to its average volume of 8,145,654. The firm’s 50 day simple moving average is $1.70 and its 200 day simple moving average is $1.85. Azitra has a 1 year low of $0.52 and a 1 year high of $3.91.

Azitra (NYSEAMERICAN:AZTR – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.04). As a group, research analysts expect that Azitra will post -2.05 earnings per share for the current fiscal year.

Azitra Company Profile

(Get Free Report)

Azitra, Inc. is a biotechnology company developing treatments for skin diseases using live biotherapeutic products based on bacteria that naturally inhabit the skin. Its approach includes engineering skin-associated bacteria to deliver therapeutic proteins directly to the skin. The company’s pipeline includes ATR-12, a candidate being developed for Netherton syndrome, a rare genetic skin disorder, and ATR-04, a candidate intended to address skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitor cancer treatments.

Featured Stories

Receive News & Ratings for Azitra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azitra and related companies with MarketBeat.com's FREE daily email newsletter.